Nature CommunicationsGenomicsPeer-reviewed journal article
Genome-wide discovery of somatic coding and regulatory variants in Diffuse Large B-cell Lymphoma
Sarah E. ArthuriD, Aixiang JiangiD, Bruno M. GrandeiD, Miguel AlcaideiD, Razvan CojocaruiD, Christopher K. RushtoniD, Anja MottokiD, Laura K. HiltoniD, Prince Kumar Lat, Eric Y. Stutheit-ZhaoiD, Luka CulibrkiD, Daisuke EnnishiiD, Selin JessaiD, Lauren C. ChongiD, Nicole ThomasiD, Prasath PararajalingamiD, Barbara MeissneriD, Merrill BoyleiD, Jordan Davidson, Kevin R. Bushell, Daniel LaiiD, Pedro FarinhaiD, Graham W. SlackiD, Gregg B. MoriniD, Sohrab P. ShahiD, , Ryan D. MoriniD
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Many known driver mutations are over-represented in one of its two molecular subgroups, knowledge of which has aided in the development of therapeutics that target these features. The heterogeneity of DLBCL determined through prior genomic analysis suggests an incomplete understanding of its molecular aetiology, with a limited diversity of genetic events having thus far been attributed to the activated B-cell (ABC) subgroup. Through an integrative genomic analysis we uncovered genes and non-coding loci that are commonly mutated in DLBCL including putative regulatory sequences. We implicate recurrent mutations in the 3UTR of NFKBIZ as a novel mechanism of oncogene deregulation and found small amplifications associated with over-expression of FC-{gamma} receptor genes. These results inform on mechanisms of NF-{kappa}B pathway activation in ABC DLBCL and may reveal a high-risk population of patients that might not benefit from standard therapeutics.
- organism: human
- assay: whole-exome sequencing
- research focus: variant calling
- approach: statistical model
- Citations
- 146
- FWCI
- 13.11
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Non-coding NFKBIZ 3' UTR mutations promote cell growth and resistance to targeted therapies in diffuse large B-cell lymphoma
S. E. Arthur, J. Gao, … R. D. Morin·bioRxiv·May 22, 2021
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma
Neeraj Kumar Jain, Keenan T. Hartert, … Michael R. Green·Science Translational MedicinePeer-reviewed·Jun 19, 2019
- Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma
Man Chun John Ma, Saber Tadros, … Michael R. Green·HaematologicaPeer-reviewed·Apr 1, 2021
- BCL10 Gain-of-Function Impairs Germinal Center Participation by Naive B Cells and Cooperates with BCL6 to Drive Extrafollicular Diffuse Large B-Cell Lymphoma
Dhanvantri Chahar, Abdessamad Alaoui Youssfi, … Jonathan H Schatz·bioRxiv·Nov 5, 2026
- Systems biology-enabled targeting of NF-κB and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.
Aimilia Vareli, Haripriya Vaidehi Narayanan, … Simon A. Mitchell·Cell Death and DiseasePeer-reviewed·Aug 16, 2025
- Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma
Calixte Calaud, Emilio M. Serrano-López, … Pilar M. Domínguez·Blood NeoplasiaPeer-reviewed·Mar 2, 2026